Patheon NV (PTHN) Given Consensus Rating of “Hold” by Brokerages
Patheon NV (NASDAQ:PTHN) has been given an average recommendation of “Hold” by the thirteen analysts that are presently covering the stock, Marketbeat reports. Eight analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $32.43.
A number of analysts have commented on PTHN shares. Jefferies Group LLC reaffirmed a “buy” rating and set a $32.00 target price (down previously from $33.00) on shares of Patheon NV in a report on Friday, March 17th. Zacks Investment Research raised shares of Patheon NV from a “hold” rating to a “buy” rating and set a $39.00 target price for the company in a report on Friday, May 19th. Raymond James Financial, Inc. reaffirmed a “market perform” rating and set a $35.00 target price on shares of Patheon NV in a report on Thursday, June 8th. William Blair lowered shares of Patheon NV from an “outperform” rating to a “market perform” rating in a report on Monday, May 15th. Finally, Leerink Swann lowered shares of Patheon NV from an “outperform” rating to a “market perform” rating and lifted their target price for the stock from $31.00 to $35.00 in a report on Friday, June 9th.
Patheon NV (NASDAQ:PTHN) traded down 0.03% during midday trading on Tuesday, hitting $34.86. The stock had a trading volume of 488,411 shares. The stock’s 50-day moving average is $34.25 and its 200-day moving average is $29.80. Patheon NV has a one year low of $23.72 and a one year high of $35.10. The company has a market cap of $5.06 billion and a P/E ratio of 44.69.
Patheon NV (NASDAQ:PTHN) last released its earnings results on Thursday, June 8th. The company reported $0.20 EPS for the quarter, topping analysts’ consensus estimates of $0.19 by $0.01. The business had revenue of $483.40 million for the quarter, compared to analyst estimates of $466.08 million. The firm’s revenue was up 3.2% on a year-over-year basis. Equities analysts predict that Patheon NV will post $1.14 EPS for the current fiscal year.
Large investors have recently bought and sold shares of the stock. Bank of New York Mellon Corp boosted its stake in Patheon NV by 0.8% in the first quarter. Bank of New York Mellon Corp now owns 90,080 shares of the company’s stock valued at $2,373,000 after buying an additional 698 shares in the last quarter. Alliancebernstein L.P. boosted its stake in Patheon NV by 25.9% in the first quarter. Alliancebernstein L.P. now owns 13,027 shares of the company’s stock valued at $343,000 after buying an additional 2,678 shares in the last quarter. Forward Management LLC boosted its stake in Patheon NV by 67.4% in the first quarter. Forward Management LLC now owns 8,714 shares of the company’s stock valued at $230,000 after buying an additional 3,509 shares in the last quarter. UBS Group AG boosted its stake in Patheon NV by 57.9% in the first quarter. UBS Group AG now owns 11,072 shares of the company’s stock valued at $291,000 after buying an additional 4,062 shares in the last quarter. Finally, Quantbot Technologies LP bought a new stake in Patheon NV during the first quarter valued at approximately $185,000.
Patheon NV Company Profile
Patheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company’s segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products.
Receive News & Ratings for Patheon NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Patheon NV and related companies with MarketBeat.com's FREE daily email newsletter.